PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
PARP inhibitors (PARPi) gained major interest among prostate cancer researchers in the last few years, thanks to the outstanding results coming from the PROfound an TRITON2 studies. Following that, PARPi gained approval also in metastatic, castration-resistant prostate cancer (mCRPC) with mutations...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Elsevier
2022
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/4b9b8948a268496481a7274502e56def |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|